Sanofi healthcare receives CDSCO approval for Qftilia therapy for haemophilia patients in India

Sanofi Healthcare has obtained authorisation from the Central Drugs Standard Control Organisation for Qfitlia. This therapy is designed to prevent bleeding in haemophilia patients aged 12 years and older. Qfitlia offers unique protection for Haemophilia A and B patients, requiring only six injections annually. The approval follows promising results from the ATLAS phase 3 clinical trials. This advancement aims to enhance access to treatment options for patients in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XE29pxY
via IFTTT

Read More

Dr Reddy's gets DCGI nod for Zytorvi in advanced esophageal cancer

Dr Reddy's Laboratories has received approval for Zytorvi, an immunotherapy targeting advanced esophageal squamous cell carcinoma. This new indication allows treatment for adult patients with a combination of toripalimab, cisplatin, and paclitaxel. Approximately 80 percent of esophageal cancer cases in India are attributed to esophageal squamous cell carcinoma. The approval derives from positive results in the Phase 3 JUPITER-06 trial.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/72My0Yt
via IFTTT

Read More

HealthRail: Turning India's hospital receivables into growth capital

In a strategic move to streamline hospital cash flow, HealthRail is offering expedited access to accrued revenues. This initiative specifically addresses the payment delays that hospitals experience with insurance providers and public funding programs. By lowering days sales outstanding for qualifying receivables, this system aims to substantially bolster hospitals' liquidity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LBOoExe
via IFTTT

Read More

NATCO Pharma subsidiary launches Carboplatin in US market to address shortages

Indian pharmaceutical company NATCO Pharma annouced the launch of Carboplatin Injection, a generic version of Paraplatin in the US market by its American subsidiary. The subsidiary would collaborate in manufacturing with Chennai-based Tero Labs Pvt Ltd. The launch is aimed at meeting the shortage of the drug. Carboplatin is directed towards the treatment of advanced ovarian carcinoma, including first-line combination therapy and palliative treatment of recurrent disease after prior chemotherapy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rDpavA1
via IFTTT

Read More

AIIMS doctors identify ‘Red Alert Zone’ to reduce risks in complex cancer surgery

AIIMS doctors have recognized two critical anatomical zones during complex cancer surgeries in women. These zones help reduce bleeding and prevent injuries to vital organs. One zone, known as 'Ray's Zone', is crucial for surgeries involving the pelvic area. The other, 'Ray's Hepatocaval Triangle', assists during liver mobilization near major vessels. Identifying these zones enhances surgical precision and patient outcomes in oncological procedures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MPDFt6b
via IFTTT

Read More

The burden of cancer drugs: Millions battle exorbitant prices as life-saving treatment slips out of reach

For millions of cancer patients, the cost of treatment can be as frightening as the diagnosis. From steep markups to patented drugs that remain out of reach, the affordability crisis runs deep. A proposed cap may help, but question remains if it will be enough to change the picture.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d2JXKVZ
via IFTTT

Read More

Aayush Wellness launches calcium, vitamin supplements; enters USD 16.3-bn bone & joint health segment

Aayush Wellness Limited has launched Aayush Calcium Vitamin Tablets, expanding its nutraceutical portfolio into the bone and joint health segment. The formulation combines calcium citrate, vitamin D2, magnesium, zinc and folic acid to support bone strength, calcium absorption and musculoskeletal health. The company said the launch aligns with growing consumer interest in preventive healthcare and nutritional supplements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vgTbfzQ
via IFTTT

Read More

NPPA caps trade margins on 137 cancer drugs at 30%, revised prices from Nov 9

India's National Pharmaceutical Pricing Authority has capped trade margins for 137 anti-cancer drugs at 30% of their maximum retail price. This cap, effective from November 9, applies to all listed drugs, including Atezolizumab and Bevacizumab. Manufacturers must adjust prices if they exceed the newly calculated maximum retail price. Compliance will be monitored by state drug controllers and hospitals, which play a significant role in drug supply.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5ABuEGc
via IFTTT

Read More

Shridevi Institute, US-based Vaxonyx sign MoU for AI-driven cancer and genomic research

Shridevi Institute of Medical Sciences in Tumakuru has signed an MoU with Vaxonyx LLC for collaboration. This partnership aims to focus on AI-enabled bioinformatics and genomic research tailored for Indian populations. They will develop personalized cancer therapies by analyzing individual tumor profiles. The collaboration will also explore the creation of genomic datasets to improve genetic models. Moreover, they intend to develop DNA-based vaccine candidates for relevant public health issues.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nj7thfi
via IFTTT

Read More

NITI Aayog explores policies to boost India's medical and dental device manufacturing industry

NITI Aayog is exploring policy measures to improve the manufacturing capabilities of medical and dental devices in India. The meeting included domestic manufacturers, government officials, and experts from IIT Delhi and IIT Mumbai. Key challenges such as regulatory hurdles and cost disadvantages faced by Indian manufacturers were discussed extensively. The industry body AiMeD emphasized the need for simpler regulations and financial support for local manufacturers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OU16ieb
via IFTTT

Read More

HLL Lifecare launches eStore to expand direct-to-consumer reach

State-owned company HLL Lifecare launched HLL eStore, a digital platform aimed to expand access to its healthcare and wellness products across the country. The platform would be part of its broader digital transformation strategy, enabling customers, business partners and healthcare institutions to engage with the company through an integrated online marketplace. The eStore also offers medical products and supplies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XZRSFnY
via IFTTT

Read More

AYUSH sees rise in patents filings showcasing innovation growth; 4,077 applications filed from 2014 to 2026

Ayush-related Intellectual Property activity has seen substantial growth, with over 4,000 patent applications from 2014 to 2026. The Ministry of Ayush emphasises the increasing participation of individuals and institutions in this sector. Patent filings peaked post-COVID, reflecting a focus on research and innovation. Natural persons and educational institutions contributed significantly to the total filings and grants. The government continues to foster an enabling environment for traditional knowledge and scientific research.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lxD4gmf
via IFTTT

Read More

India needs 2.6 billion sq ft of healthcare space by 2035, says CBRE

India requires an expansion of its healthcare infrastructure with an additional 2.6 billion sq ft by 2035. This need arises due to an expected demand for nearly 2.9 million more hospital beds nationwide. Current statistics show India has only 1.6 hospital beds per 1,000 people, significantly less than the global average. Certain states face much lower hospital bed density compared to their disease burden, indicating unmet healthcare needs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rfzT6tg
via IFTTT

Read More

Indian, German firms to collaborate on immunoglobulin products: Indian Embassy

Germany's Neovii Biotech and India's VINS Bioproducts will explore collaboration on manufacturing and commercialising immunoglobulin products, including anti-thymocyte globulin used in organ transplantation and certain blood disorders. Facilitated by the Indian Embassy in Berlin, the agreement involves technology transfer to India and could strengthen domestic capabilities in specialised biological products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VT6fGIw
via IFTTT

Read More

Biocon settles US patent dispute with Roche's Genentech, eyes 2027 Perjeta biosimilar launch

Biocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta. The agreement allows Biocon to launch Pebrilzo in early 2027 in the UK and EU, and in late 2028 in the US. In response to Genentech's patent infringement suit, the New Jersey court dismissed the case at Genentech's request. The details of the settlement agreement remain confidential between the companies involved.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NhPxSjv
via IFTTT

Read More

Novo Holdings, GIC, Axight look to back AIG Hospitals; Founders aim to pare 10-12% stake at Rs 24,000 cr valuation

Novo Holdings and GIC are discussing investing Rs 2,000-2,500 crore in AIG Hospitals based in Hyderabad. The investment reflects a growing interest among private equity firms in Indian healthcare. Founders of AIG Hospitals, Duvvur Nageshwar Reddy and Penmetsa Venkata Subbaraju, are planning a stake sale. AIG Hospitals has plans for a new facility in Visakhapatnam and aims to grow significantly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/e4M9VTd
via IFTTT

Read More

Health ministry asked to examine coronary stent safety concerns

Cabinet secretariat has directed the Union health ministry to investigate safety issues related to coronary stents. These concerns were raised by Rajya Sabha member Ajeet Madhavrao Gopchade regarding models withdrawn in Sri Lanka. Gopchade emphasized the need for strengthening India's regulatory framework for coronary stents. He called for improved clinical documentation and robust traceability for implanted stents. His representation highlighted the importance of patient follow-up and monitoring of device-related complications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/k5eM81q
via IFTTT

Read More

Biocon clears path for cancer drug launch

Biocon has finalized a global settlement and license agreement with Genentech for its drug Pebrilzo. This agreement addresses all ongoing legal disputes between the two companies in jurisdictions such as the US and Canada. Under the terms, Biocon can launch Pebrilzo in the EU and UK by early 2027 and in the US by Q3 of 2028. Other global launches are planned between 2026 and 2028, depending on regulatory approvals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3YycUMS
via IFTTT

Read More

NMC Healthcare founder BR Shetty files $15 billion lawsuit against Bank of Baroda

The suit, filed in the Bombay High Court, seeks $5 billion in direct damages for alleged fraud and negligence, $5 billion in consequential damages and $5 billion in compensation for reputational harm arising from various actions taken by the bank, including a lookout circular issued against him.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5WdTHKj
via IFTTT

Read More

Biocon founder Kiran Mazumdar Shaw says India must shift pharma industry from generics to innovation-led growth

Kiran Mazumdar-Shaw emphasized the importance of building an innovation-driven pharmaceutical industry in India. She highlighted the need for continued investment in research and regulatory reforms to enhance drug development. The industry must focus on maintaining high-quality standards as it seeks to innovate. Closer cooperation between industry and regulators can help sustain momentum during this transition. India has the potential to participate actively in the global innovation ecosystem.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0UTfv9L
via IFTTT

Read More

Zydus moves closer to US market for Keytruda biosimilar as FDA accepts application

Zydus Lifesciences has received acceptance for its application regarding the biosimilar of Keytruda, which is a major cancer drug. The USFDA is expected to complete its review process by the third quarter of 2027. This biosimilar, named FYB206, was developed without a comparative Phase III efficacy trial. Zydus aims to make effective treatments more accessible in the oncology field in North America.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dk6iDnb
via IFTTT

Read More

Panel to finalise cancer drugs for 30% trade margin cap; Rs 2,500 crore annual savings possible

An expert group is finalizing the list of cancer medicines for a new trade margin cap. The government plans to implement a 30% cap to reduce drug prices and save patients money. Retail prices of some anti-cancer drugs could drop by up to 70% as a result of this cap. The trade margin rationalisation will apply to all cancer medicines, including branded and generic versions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WohERwL
via IFTTT

Read More

Supreme Court questions govt over drug pricing, asks why cap limited to anti-cancer medicines

The Supreme Court expressed its worry over the government's restriction of price control measures to only anti-cancer drugs, questioning why other vital medications lack similar oversight when sold at exorbitant rates. The Solicitor General emphasized the importance of maintaining a balance between drug availability and market dynamics in determining prices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Luz1p5H
via IFTTT

Read More

Joint pain isn’t the same for everyone. Should treatment be?

Joint pain is frequently dismissed as an inevitable consequence of aging; however, it may point to significant underlying issues. Symptoms like stiffness and inflammation warrant a consultation with healthcare professionals. Various forms of arthritis necessitate unique treatment approaches, and symptoms can differ from person to person. Maintaining an active lifestyle and a healthy weight is crucial for preserving joint health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KfBZET3
via IFTTT

Read More

Roche calls for global healthcare overhaul to tackle disease burden

Roche highlights the urgent need for a transformation in global healthcare to effectively tackle chronic diseases. Jorg Rupp pointed out that existing healthcare infrastructures are largely reactive, falling short in proactively addressing the rise of non-communicable diseases. This burgeoning issue not only challenges health systems but also imposes heavy financial demands. Governments must begin viewing healthcare as a crucial investment aimed at enhancing health outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BQphSg0
via IFTTT

Read More

Tricog Health targets 100 million cardiac screenings by 2030: CEO Dr Charit Bhograj

Bengaluru-based Tricog Health aims to conduct 100 million cardiac screenings by 2030, having screened over 41 million patients since its founding in 2014. The healthtech firm uses AI-enabled ECG devices and specialist reviews to detect heart conditions, with operations across several Indian states and 14 countries. Its technology aims to reduce diagnosis delays and improve early detection of cardiovascular diseases.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fBrLahj
via IFTTT

Read More

Indian pharma's risk aversion holding back innovation: Kiran Mazumdar-Shaw

Biocon chairperson Kiran Mazumdar-Shaw calls for greater use of digital technology to speed up drug development, as industry leaders push for a shift beyond generics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1Sm9YKA
via IFTTT

Read More

Health ministry proposes curbs on prescription drug ads by retailers, wholesalers and distributors

The union health ministry has proposed extending advertising restrictions on prescription drugs to retailers and distributors. This change will bar them from advertising certain medicines without prior government approval. The amendment affects drugs covered under Schedules H, H1, and X, which require medical oversight. The existing regulations already apply to pharmaceutical manufacturers. The recommendation for this amendment comes from the Drugs Technical Advisory Board.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FKdI3EX
via IFTTT

Read More

Experiments on animals set to become easier

The Centre plans to significantly change the regulations governing animal experimentation. The proposed rules aim to allow institutional ethics panels to approve most experiments. Currently, only small animal experiments can be approved at the institutional level while larger ones require central oversight.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AKjUpnS
via IFTTT

Read More

Hair fall decoded: Causes, triggers, and warning signs

For many, hair shedding can raise concerns, with various elements at play like stress, hormonal imbalances, and nutrition. Recognizing the difference between shedding and breakage is essential, as each has distinct roots and remedies. Noting specific loss patterns can guide you towards effective treatments. Additionally, seeking expert guidance can shed light on potential health issues impacting your hair's condition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/L1l56pJ
via IFTTT

Read More

National Medical Commission bans doctors & hospitals from using AI-generated patient testimonials, fake cure claims in medical ads

The National Medical Commission has implemented new ethical advertising guidelines affecting doctors and hospitals. These guidelines prohibit the use of artificial intelligence for generating promotional content or testimonials. Measures have also been taken to restrict paid patient solicitation and misleading claims in advertisements. Strict penalties have been established for non-compliance, including warnings and license suspensions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GCsa0t7
via IFTTT

Read More

Govt set to cap trade margins on more cancer drugs before SC hearing

The Indian government plans to announce a new list of cancer drugs for trade margin rationalisation today. Union Health Minister JP Nadda will make the announcement just ahead of a Supreme Court hearing on October 12. This decision comes after concerns regarding the price gap between retailer prices and MRP of some cancer medications. Trade margins were capped previously, leading to significant price reductions on several anti-cancer drugs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WawMSEi
via IFTTT

Read More

Supreme Court seeks committee to curb pharma firms’ unethical marketing practices

The Supreme Court has directed the government to form a committee regarding pharmaceutical marketing regulations. This follows concerns over unethical practices influencing doctors’ prescribing decisions and patient health outcomes. Petitioners are advocating for stronger legal frameworks beyond the current voluntary code. They emphasize the need for a statutory code supported by penalties to protect the right to health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OuafslW
via IFTTT

Read More

Ayush services sector supports 1.76 million livelihoods; women constitute 43% of the workforce

The Ayush services sector supports 1.76 million livelihoods in India and has a significant female workforce. Women's participation in organized segments, including hospitals, exceeds 50 percent in several areas. The sector has the potential to expand substantially, generating an estimated USD 216-318 billion by 2047. Ayurveda remains the largest individual system of revenue generation within the sector, contributing significantly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8vEpzIN
via IFTTT

Read More

The 30-Minute Medicine Problem

How India's largest ePharmacy is building an in-house quick-commerce engine across cities and why moving medicines in under an hour is far more complicated than it looks

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/c4NTo3D
via IFTTT

Read More

Drug panel rejects child images on cough syrup labels, proposes age warning for use below 4 years

Cough syrup bottles will soon include a prominent red warning stating their use is not recommended for children under four. An expert committee rejected child-oriented imagery on labels, which could imply suitability for young children. This decision follows ongoing concerns about the safety of cough syrups in pediatric care. The proposed change aims to prevent confusion regarding age restrictions for these medications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BwgnLQy
via IFTTT

Read More

Lord’s Mark strengthens UK and UK allied market strategy with regulatory backing for IVD portfolio.

In an exciting development, Lord's Mark Industries has secured registration for its In-Vitro Diagnostic portfolio with the MHRA, significantly boosting market access. This follows the approval of their AI-enhanced Renalyx haemodialysis system in the UK. The firm aims for a December 2026 market launch for its IVD products, ahead of schedule, along with a planned January 2027 start for its pathology lab, highlighting its strong commitment to global healthcare integration.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hoce1DA
via IFTTT

Read More

Centre may seek legal view on licensing of sterile drugs

The government is actively exploring a proposal to expand central licensing authority over all sterile drug products following a recent Supreme Court decision that restricted the enforcement authority of central officials. A meeting of the drugs consultative committee underscored the essential requirement for specialized regulatory oversight for these sensitive products, aiming for uniform regulations. A dedicated sub-committee will evaluate the proposal's feasibility and gather legal insights before any definitive actions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p6l2iYZ
via IFTTT

Read More

Ayush services sector supports 1.76 million livelihoods; women constitute 43% of the workforce

The Ayush services sector supports 1.76 million livelihoods in India and has a significant female workforce. Women's participation in organized segments, including hospitals, exceeds 50 percent in several areas. The sector has the potential to expand substantially, generating an estimated USD 216-318 billion by 2047. Ayurveda remains the largest individual system of revenue generation within the sector, contributing significantly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zRjr0f8
via IFTTT

Read More

Wall Street’s $10 billion India hospital bet sparks a fight over bills

Wall Street has poured about $10 billion into Indian hospital chains over the past five years, with investors including Blackstone, KKR, TPG and General Atlantic betting on India’s huge shortage of hospital beds and rising demand for specialised care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/W2kVamB
via IFTTT

Read More

Robotic surgery gains rapid ground in India, Delhi NCR leads: Experts

India is rapidly scaling up robotic surgery, with procedures rising from 8,912 in 2021 to 44,857 in 2025, while Delhi NCR has emerged as the country’s biggest hub with 39 hospitals using robotic systems. Experts say the next phase could include wider use of telesurgery, remote mentoring and access to specialist care beyond major cities, subject to regulatory and cybersecurity safeguards.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EZDxXmd
via IFTTT

Read More

Maharashtra FDA cancels Cipla's Pune warehouse licences over Reactin Plus packaging claims

Maharashtra's Food and Drug Administration has cancelled Cipla Pharma's distribution licenses due to serious violations. The FDA discovered irregularities with Reactin Plus Tablets, including misbranding and unsafe storage practices. Following inspections, it was revealed that expired medicines were stored incorrectly without proper documentation. The licensing authority’s decision was based on findings from earlier proceedings and legal directions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lwzvNLP
via IFTTT

Read More

India has biotech talent and know-how, but funding ecosystem lags: Lilly CEO

Eli Lilly intends to innovate in the weight-loss market, launching up to four new products in the coming years. The success of Mounjaro and Zepbound significantly boosted the company's sales and market value. Eli Lilly sees potential in India's biotech sector, despite challenges in the research funding environment. The company is open to partnerships with Indian biotechnology firms for future collaborations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/v7L6naV
via IFTTT

Read More

‘India’s biotech ecosystem holds tremendous promise’: Eli Lilly CEO

Eli Lilly has experienced significant growth, reaching a market capitalization over $1 trillion. The company aims to maintain its leadership in anti-obesity drugs through ongoing innovation and development. With successful trials for drugs like retatrutide and Foundayo, Lilly is expanding its product offerings. The company recognizes the importance of India as a growing market for healthcare investments and partnerships.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/s7BoJzj
via IFTTT

Read More

Karnataka flags 52x mark-up on cancer drugs, seeks Centre's intervention

Karnataka conducted inspections revealing significant price disparities between hospital procurement and patient billing for cancer drugs and medical devices. The state government has urged the Centre to implement transparency in pricing and regulate trade margins for essential medicines. Mark-ups observed ranged from 10 to over 52 times the actual procurement costs for various items.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xKPHXfq
via IFTTT

Read More

Rasayan Labs launches AI-native drug discovery platform at ICT Mumbai

In an exciting development, Rasayan Labs has unveiled a groundbreaking AI-based platform to enhance computational chemistry and drug discovery initiatives. This innovative platform merges critical functions, including retrosynthesis and ADMET prediction, to optimize research efficiency. Free access will be granted to researchers at the Institute of Chemical Technology, marking a pivotal collaboration that seeks to dramatically reduce drug development timelines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KhXkoyt
via IFTTT

Read More